Corvus Pharmaceuticals (CRVS) Competitors $5.41 -0.09 (-1.64%) Closing price 04:00 PM EasternExtended Trading$5.49 +0.08 (+1.46%) As of 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRVS vs. AUPH, WVE, JANX, EWTX, ARDX, HROW, SPRY, SDGR, AMPH, and VERAShould you be buying Corvus Pharmaceuticals stock or one of its competitors? The main competitors of Corvus Pharmaceuticals include Aurinia Pharmaceuticals (AUPH), WAVE Life Sciences (WVE), Janux Therapeutics (JANX), Edgewise Therapeutics (EWTX), Ardelyx (ARDX), Harrow (HROW), ARS Pharmaceuticals (SPRY), Schrodinger (SDGR), Amphastar Pharmaceuticals (AMPH), and Vera Therapeutics (VERA). These companies are all part of the "pharmaceutical products" industry. Corvus Pharmaceuticals vs. Its Competitors Aurinia Pharmaceuticals WAVE Life Sciences Janux Therapeutics Edgewise Therapeutics Ardelyx Harrow ARS Pharmaceuticals Schrodinger Amphastar Pharmaceuticals Vera Therapeutics Corvus Pharmaceuticals (NASDAQ:CRVS) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership. Which has higher valuation & earnings, CRVS or AUPH? Aurinia Pharmaceuticals has higher revenue and earnings than Corvus Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorvus PharmaceuticalsN/AN/A-$62.29M-$1.01-5.36Aurinia Pharmaceuticals$260.11M6.11$5.75M$0.4328.09 Is CRVS or AUPH more profitable? Aurinia Pharmaceuticals has a net margin of 23.31% compared to Corvus Pharmaceuticals' net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 20.06% beat Corvus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Corvus PharmaceuticalsN/A -28.61% -18.05% Aurinia Pharmaceuticals 23.31%20.06%13.81% Do analysts prefer CRVS or AUPH? Corvus Pharmaceuticals presently has a consensus target price of $15.00, indicating a potential upside of 177.26%. Aurinia Pharmaceuticals has a consensus target price of $12.00, indicating a potential downside of 0.66%. Given Corvus Pharmaceuticals' higher possible upside, equities analysts plainly believe Corvus Pharmaceuticals is more favorable than Aurinia Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corvus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Aurinia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders have more ownership in CRVS or AUPH? 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 28.5% of Corvus Pharmaceuticals shares are owned by company insiders. Comparatively, 12.2% of Aurinia Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media prefer CRVS or AUPH? In the previous week, Aurinia Pharmaceuticals had 2 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 4 mentions for Aurinia Pharmaceuticals and 2 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.62 beat Aurinia Pharmaceuticals' score of 1.44 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corvus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Aurinia Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, CRVS or AUPH? Corvus Pharmaceuticals has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. SummaryAurinia Pharmaceuticals beats Corvus Pharmaceuticals on 9 of the 14 factors compared between the two stocks. Get Corvus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRVS vs. The Competition Export to ExcelMetricCorvus PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$403.12M$3.06B$5.76B$9.84BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-5.3621.1931.3126.63Price / SalesN/A392.62461.66121.17Price / CashN/A44.4437.7659.36Price / Book5.018.0710.026.69Net Income-$62.29M-$54.08M$3.27B$265.59M7 Day Performance2.27%2.32%3.17%3.44%1 Month Performance16.34%3.47%4.36%1.12%1 Year Performance31.95%18.51%44.16%23.91% Corvus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRVSCorvus Pharmaceuticals3.2289 of 5 stars$5.41-1.6%$15.00+177.3%+35.1%$403.12MN/A-5.3630AUPHAurinia Pharmaceuticals2.9939 of 5 stars$12.22-0.4%$12.00-1.8%+79.9%$1.62B$260.11M28.42300Positive NewsWVEWAVE Life Sciences4.775 of 5 stars$9.74-0.2%$20.27+108.1%+78.4%$1.55B$93.95M-10.82240Insider TradeJANXJanux Therapeutics2.5531 of 5 stars$25.53+1.7%$91.89+259.9%-48.3%$1.51B$10.59M-14.1830News CoveragePositive NewsEWTXEdgewise Therapeutics2.318 of 5 stars$14.00-1.1%$41.60+197.1%-26.9%$1.49BN/A-9.0360ARDXArdelyx4.1399 of 5 stars$5.81-2.7%$11.50+97.9%-0.5%$1.44B$386.15M-25.2690News CoverageInsider TradeHROWHarrow3.4433 of 5 stars$38.32-1.3%$64.67+68.8%-10.6%$1.44B$199.61M-153.28180Analyst RevisionSPRYARS Pharmaceuticals2.4031 of 5 stars$14.03-3.4%$31.00+121.0%-3.7%$1.44B$89.15M-28.6390SDGRSchrodinger2.8535 of 5 stars$20.05+3.5%$27.83+38.8%-4.0%$1.43B$207.54M-8.08790AMPHAmphastar Pharmaceuticals3.396 of 5 stars$29.76-0.2%$31.50+5.8%-37.1%$1.39B$731.97M11.152,028News CoveragePositive NewsAnalyst ForecastVERAVera Therapeutics3.8356 of 5 stars$21.80+1.2%$63.00+189.0%-41.5%$1.37BN/A-6.0940News CoveragePositive News Related Companies and Tools Related Companies Aurinia Pharmaceuticals Alternatives WAVE Life Sciences Alternatives Janux Therapeutics Alternatives Edgewise Therapeutics Alternatives Ardelyx Alternatives Harrow Alternatives ARS Pharmaceuticals Alternatives Schrodinger Alternatives Amphastar Pharmaceuticals Alternatives Vera Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRVS) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump's "Big Beautiful Bill" hides ugly truthWashington’s new “Big Beautiful Bill” promises tax breaks… but the fine print tells a different story: trillio...Defi Master | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corvus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access